Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anorexia
Megestrol phase II proof-of-concept study results reported
August 26th, 2005
Par Pharmaceutical Companies, Inc., (PRX) announced results of a phase II proof-of-concept clinical trial with concentrated megestrol acetate oral suspension that utilizes NanoCrystal Technology. In the trial, patients taking concentrated megestrol acetate 575 mg/5 mL gained more weight, on average, than those taking the older megestrol acetate oral suspension 800 mg/20 mL. "The results of this proof-of-concept study are very encouraging," said Shankar Hariharan, PhD, executive vice president and chief scientific officer. "Although this study was not powered to achieve statistical significance, there was a substantial difference in mean weight gain,...
Source: Drug Week (2005-08-26)
|
